Newswise — NEW YORK, NY – September 13, 2016 – The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 29 – November 2, 2016 at the Walter E. Washington Convention Center in Washington, DC.
Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that will impact patient care and how physicians treat heart disease. The studies selected will examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, the leading cause of death in the world. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Sunday, October 30; Monday, October 31; Tuesday, November 1; and Wednesday, November 2. TCT press conferences will be held each morning beginning at 7:30 AM ET.
The complete agenda for TCT 2016 is now available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty. Media are invited to attend TCT. To apply for media credentials, visit: http://www.crf.org/tct/press/press-registration-form.
Sunday, October 30Late-Breaking TrialsILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery DiseaseZiad A. Ali BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients with Coronary Artery DiseaseClemens von Birgelen
BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs. a Zotarolimus-Eluting Stent in a More-Comers Population of Patients with Coronary Artery DiseaseDavid E. Kandzari
First Report InvestigationsABSORB China: Two-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery DiseaseRunlin Gao
ABSORB II: Three-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery DiseasePatrick W. Serruys
LEADERS FREE: Two-Year Clinical and Subgroup Outcomes from a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients with Coronary Artery Disease at High Bleeding RiskPhilip M. Urban
Monday, October 31Late-Breaking TrialsEXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery DiseaseGregg W. Stone NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery DiseaseEvald H. Christiansen
First Report InvestigationsREVELUTION: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes with a Polymer-Free Sirolimus-Eluting Drug-Filled Stent Stephen G. Worthley FANTOM II: 6-Month and 9-Month Clinical, Angiographic and OCT Results with a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery DiseaseAlexandre Abizaid
MeRes-1: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery DiseaseAshok Seth FORTITUDE: 9-Month Clinical, Angiographic, and OCT Results with an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery DiseaseAntonio Colombo FUTURE-I: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease Bo Xu
Tuesday, November 1Late-Breaking TrialsSENTINEL: A Prospective, Randomized Trial Evaluating Cerebral Protection in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve ReplacementSusheel Kodali PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate Risk Patients with Severe Aortic Stenosis David J. Cohen PARTNER I FIVE-YEAR ECHO: Long-Term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients with Aortic StenosisPamela S. Douglas
First Report InvestigationsRESPECT: Final Long-Term Outcomes From a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic StrokeDavid E. Thaler
COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes after Stent Implantation in Patients with Coronary Artery DiseaseGiora Weisz PLATINUM DIVERSITY: Outcomes from a Large-Scale, Prospective Registry of Coronary Artery Stent Implantation in Women and MinoritiesWayne B. Batchelor
ReACT: A Prospective, Randomized Trial of Routine Angiographic Follow-up After Coronary Artery Stent ImplantationHiroki Shiomi
Wednesday, November 2Late-Breaking Trials ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal ArteriesSean P. Lyden
WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial FibrillationVivek Y. Reddy AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation David Hildick-Smith
First Report InvestigationsPRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients with Coronary Artery Chronic Total OcclusionsKoen Teeuwen
TOSCA-5: A Prospective, Randomized Trial Evaluating Collagenase Infusion in Patients with Coronary Artery Chronic Total OcclusionsChristopher E. Buller TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at 3 Months and Neoatherosclerosis at 18 Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting StentsGiulio Guagliumi
RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis – 6-9 Month Clinical and Angiographic Follow-up ResultsFernando Alfonso
Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.
About CRF and TCTThe Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Now in its 28th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. For more information, visit www.crf.org and www.tctconference.com.
###
RSS